DarioHealth Corp. (DRIO) financial statements (2021 and earlier)

Company profile

Business Address 8 HATOKHEN ST.
CAESAREA, 38900
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2058711125
Cash and cash equivalents2058711115
Short-term investments     00
Restricted cash and investments00000  
Inventory, net of allowances, customer advances and progress billings1122111
Inventory1122111
Prepaid expense0   0  
Deferred costs0   0  
Other current assets0   0  
Other undisclosed current assets1111011
Total current assets:237111013147
Noncurrent Assets
Operating lease, right-of-use asset11  
Property, plant and equipment1111111
Deposits noncurrent assets0000000
Other undisclosed noncurrent assets0 11   
Total noncurrent assets:2122111
TOTAL ASSETS:259121114148
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4123422
Accounts payable2123322
Accrued liabilities1   1  
Employee-related liabilities1   1  
Deferred revenue11  
Debt00     
Other undisclosed current liabilities 134122
Total current liabilities:5467544
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Total noncurrent liabilities:00     
Total liabilities:6567544
Stockholders' equity
Stockholders' equity attributable to parent194649104
Common stock 000000
Additional paid in capital12910710698989584
Accumulated deficit(110)(103)(100)(95)(89)(84)(80)
Total stockholders' equity:194649104
Other undisclosed liabilities and equity  11   
TOTAL LIABILITIES AND EQUITY:259121114148

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues2222222
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)(1)(2)(1)(1)(2)
Gross profit:1101001
Operating expenses(5)(4)(6)(6)(5)(4)(6)
Operating loss:(4)(3)(5)(5)(5)(4)(6)
Nonoperating income (expense)0(0)(0)(0)0(0)(0)
Foreign currency transaction gain, before tax   0   
Other nonoperating income (expense)0(0)(0)(0)0(0)(0)
Net loss attributable to parent:(4)(3)(5)(5)(5)(4)(6)
Other undisclosed net loss available to common stockholders, basic(3)     (0)
Net loss available to common stockholders, diluted:(7)(3)(5)(5)(5)(4)(6)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(4)(3)(5)(5)(5)(4)(6)
Comprehensive loss, net of tax, attributable to parent:(4)(3)(5)(5)(5)(4)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: